- Home
- NGNE vs OLMA Comparison
NGNE vs OLMA Comparison
Compare NGNE & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- OLMA
- Stock Information
- Founded
- NGNE 2003
- OLMA 2006
- Country
- NGNE United States
- OLMA United States
- Employees
- NGNE N/A
- OLMA N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- NGNE Health Care
- OLMA Health Care
- Exchange
- NGNE Nasdaq
- OLMA Nasdaq
- Market Cap
- NGNE 352.4M
- OLMA 420.2M
- IPO Year
- NGNE N/A
- OLMA 2020
- Fundamental
- Price
- NGNE $16.62
- OLMA $5.50
- Analyst Decision
- NGNE Strong Buy
- OLMA Strong Buy
- Analyst Count
- NGNE 6
- OLMA 5
- Target Price
- NGNE $60.80
- OLMA $26.25
- AVG Volume (30 Days)
- NGNE 223.3K
- OLMA 1.3M
- Earning Date
- NGNE 11-18-2024
- OLMA 03-10-2025
- Dividend Yield
- NGNE N/A
- OLMA N/A
- EPS Growth
- NGNE N/A
- OLMA N/A
- EPS
- NGNE N/A
- OLMA N/A
- Revenue
- NGNE $925,000.00
- OLMA N/A
- Revenue This Year
- NGNE N/A
- OLMA N/A
- Revenue Next Year
- NGNE N/A
- OLMA N/A
- P/E Ratio
- NGNE N/A
- OLMA N/A
- Revenue Growth
- NGNE N/A
- OLMA N/A
- 52 Week Low
- NGNE $14.44
- OLMA $4.60
- 52 Week High
- NGNE $74.49
- OLMA $16.78
- Technical
- Relative Strength Index (RSI)
- NGNE 29.82
- OLMA 40.52
- Support Level
- NGNE $17.63
- OLMA $4.60
- Resistance Level
- NGNE $20.29
- OLMA $5.83
- Average True Range (ATR)
- NGNE 1.49
- OLMA 0.55
- MACD
- NGNE -0.17
- OLMA 0.16
- Stochastic Oscillator
- NGNE 7.29
- OLMA 58.06
About NGNE Neurogene Inc.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.